Xillix Technologies Corp (XLX-T) Stock Predictions - Stockchase
WATCH LIST
28
Xillix Technologies Corp (XLX-T)

ON STOCKCHASE SINCE Nov 2003

Fluorescent based endoscopy for lung cancer diagnostics

medical services

Xillix Technologies Corp

XLX-T

0 watching          
Join the Discussion

Xillix Technologies Corp (XLX-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about XLX-T



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
Small market cap of $15 million. Sales have not been as good as expected. Expected loss of $.04 in earnings in 2007.
medical services
0 0 0 0 0
0 comments
Small market cap of $15 million. Sales have not been as good as expected. Expected loss of $.04 in earnings in 2007.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.105
Owned Owned
Unknown

DON'T BUY
Have got approval from FDA. Estimates have gone down the last 90 days because they hired a large sales staff, but sales are not appearing as quickly as hoped. Earnings are expected to get better for Dec/06, but are still negative going from -$0.08 to -$0.05. Looking out to ’07, they are expecting to earn $0.01.
medical services
0 0 0 0 0
0 comments
Have got approval from FDA. Estimates have gone down the last 90 days because they hired a large sales staff, but sales are not appearing as quickly as hoped. Earnings are expected to get better for Dec/06, but are still negative going from -$0.08 to -$0.05. Looking out to ’07, they are expecting to earn $0.01.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.240
Owned Owned
Unknown

DON'T BUY
Has interesting technology that uses flourescent lighting to look inside the lungs re: early stage cancer. Ranks 678 out of 700 in the database, the bottom 10%. The market is waiting for sales to appear.
medical services
0 0 0 0 0
0 comments
Has interesting technology that uses flourescent lighting to look inside the lungs re: early stage cancer. Ranks 678 out of 700 in the database, the bottom 10%. The market is waiting for sales to appear.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.335
Owned Owned
No

WAIT
Have the FDA approval. The challenge in the recent quarter is that sales have been almost non-existant. Now ramping up their sales force which will be an increase in expenses. An excellent product, but a "wait and see" stock. Earnings may take a year, if not longer.
medical services
0 0 0 0 0
0 comments
Have the FDA approval. The challenge in the recent quarter is that sales have been almost non-existant. Now ramping up their sales force which will be an increase in expenses. An excellent product, but a "wait and see" stock. Earnings may take a year, if not longer.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.520
Owned Owned
No

VAGUE
Waiting for the FDA approval and are fairly confidant they are going to get it. Just signed a marketing agreement with Conmed (CNMD-Q) which is an expert on high tech medical equipment. These 2 things should be a great impetus to put this company considerably higher.
medical services
0 0 0 0 0
0 comments
Waiting for the FDA approval and are fairly confidant they are going to get it. Just signed a marketing agreement with Conmed (CNMD-Q) which is an expert on high tech medical equipment. These 2 things should be a great impetus to put this company considerably higher.
medical services
0 0 0 0 0
0 comments
Peter Brieger

Chairman &, GlobeInvestment Capi...

Price Price
$0.600
Owned Owned
No

DON'T BUY
Did a financing and have some cash. Earnings estimates are for losses, $0.06 in 2005 and $0.02 in 2006. Estimates have been shaved down by about 10% in the last 90 days. Next earnings are due to be reported in 2 weeks. Great product, but still waiting for approval.
medical services
0 0 0 0 0
0 comments
Did a financing and have some cash. Earnings estimates are for losses, $0.06 in 2005 and $0.02 in 2006. Estimates have been shaved down by about 10% in the last 90 days. Next earnings are due to be reported in 2 weeks. Great product, but still waiting for approval.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.640
Owned Owned
No

BUY
Have a product for finding colon/lung cancer. The innovation in terms of product will be adopted by the industry.
medical services
0 0 0 0 0
0 comments
Have a product for finding colon/lung cancer. The innovation in terms of product will be adopted by the industry.
medical services
0 0 0 0 0
0 comments
Werner Muehelem

Vice Presi, ING Funds...

Price Price
$0.750
Owned Owned
Yes

HOLD
Hoping to get the FDA pre-market approval very soon and will be able to offer their flourescent device for early lung cancer detection. Interesting speculation.
medical services
0 0 0 0 0
0 comments
Hoping to get the FDA pre-market approval very soon and will be able to offer their flourescent device for early lung cancer detection. Interesting speculation.
medical services
0 0 0 0 0
0 comments
Peter Brieger

Chairman &, GlobeInvestment Capi...

Price Price
$0.760
Owned Owned
No

WAIT
Interesting technology. They use white light, which is the conventional lighting, for looking inside the body, but also their proprietory flourescent lighting. The challenge is that the company is expected to burn a bunch of cash. Will wait for the sales to start and earnings start to turn.
medical services
0 0 0 0 0
0 comments
Interesting technology. They use white light, which is the conventional lighting, for looking inside the body, but also their proprietory flourescent lighting. The challenge is that the company is expected to burn a bunch of cash. Will wait for the sales to start and earnings start to turn.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.800
Owned Owned
No

BUY on WEAKNESS
Sold his position for tax loss reasons in December. Would like to get back in at around $0.70/0.75. A terrific company. Likes their technology. If they get FDA approval, he would expect a price of $1.85/2.00 in 12/24 months.
medical services
0 0 0 0 0
0 comments
Sold his position for tax loss reasons in December. Would like to get back in at around $0.70/0.75. A terrific company. Likes their technology. If they get FDA approval, he would expect a price of $1.85/2.00 in 12/24 months.
medical services
0 0 0 0 0
0 comments
Peter Brieger

Chairman &, GlobeInvestment Capi...

Price Price
$0.770
Owned Owned
No

HOLD
FDA gave a pass to proceed with the testing of Onco-Life, so not sure why the stock has not moved. Still likes.
medical services
0 0 0 0 0
0 comments
FDA gave a pass to proceed with the testing of Onco-Life, so not sure why the stock has not moved. Still likes.
medical services
0 0 0 0 0
0 comments
Peter Brieger

Chairman &, GlobeInvestment Capi...

Price Price
$0.700
Owned Owned
Yes

VAGUE
It is special and interesting stock.
medical services
0 0 0 0 0
0 comments
It is special and interesting stock.
medical services
0 0 0 0 0
0 comments
Peter Brieger

Chairman &, GlobeInvestment Capi...

Price Price
$0.810
Owned Owned
Yes

DON'T BUY
Has interesting technology. Ranks borderline 25% bottom part of the database. Earnings loss of $.11 improved to a loss of $.07 in 04 and $.02 for 05. Wait for FDA approval.
medical services
0 0 0 0 0
0 comments
Has interesting technology. Ranks borderline 25% bottom part of the database. Earnings loss of $.11 improved to a loss of $.07 in 04 and $.02 for 05. Wait for FDA approval.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.880
Owned Owned
No

WEAK BUY
Intermediate buy signal. Has interesting technologies. Speculative.
medical services
0 0 0 0 0
0 comments
Intermediate buy signal. Has interesting technologies. Speculative.
medical services
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$1.040
Owned Owned
Yes

BUY
Expect there will be some news out in the next 3/6 months. Good technology. A viable business.
medical services
0 0 0 0 0
0 comments
Expect there will be some news out in the next 3/6 months. Good technology. A viable business.
medical services
0 0 0 0 0
0 comments
Glenn Paradis,

Vice Presi, Aegon Capital Manage...

Price Price
$0.950
Owned Owned
Yes

Showing 1 to 15 of 28 entries
Successfully Saved Company
Successfully Saved Company
1+
JOIN THE DISCUSSION
1 comments in the last 7 days